Splash Pharmaceuticals

Splash Pharmaceuticals is a clinical stage company specializing in oncology and arthritis therapies. The company leverages its extensive experience and data to develop innovative treatments targeting CD44, a protein involved in cell communication and migration. Splash's lead candidate, SPL 108, has shown promising results in multiple clinical trials, demonstrating both safety and efficacy in over 100 human subjects. The company primarily serves patients suffering from various cancer types and arthritis, operating within the biopharmaceutical market. Splash Pharmaceuticals generates revenue through the development and potential commercialization of its therapeutic candidates, aiming to bring new, effective treatments to market.

Keywords: CD44, oncology, arthritis, clinical trials, SPL 108, cancer therapy, biopharmaceutical, safety, efficacy, innovative treatments.